FHCO investors are exsiting. APP investors "who value it at $100M" are not buying. New biotech investors are not buying. I would say the jury is no longer out...
I believe PATH is the one trying to sell its patent, not Cupid. There are two other companies who have received WHO clearance, PATH and another Indian company. PATH has partnered with a Chinese company and has done poorly with it for at least 5 years. The Indian company only focuses on India according to its "mission" but that could change.
If Zika spreads like crazy over next couple months, the deal will be voted down... there's a built in safety
Bethune, the director who led the M&A search, abstained. Not sure if conflict was because he's biased or had some other relationship with APP.
His new start-up, which in part has licensed some IP from GTXI, is merging into FHCO and creating a real disaster for the market. It's a product company that is now becoming an early stage development company, largely dependent on a number of drug candidates. It doesn't seem like he had too much success developing anything at GTXI.
Break-up fees are not paid upon failure to receive shareholder approval. The shareholder base will have turned over by September or whenever this is voted upon, so it's bunch of guys that bought in at $1.40 and understand biotech. That said, it's tough to get 67% approval regardless, given the retail shareholder base.
The PreBoost product is a wipe where the active ingredient is 4% Benzocaine. You're not far off...
They didn't say that. $110M over 4-5 years assuming they try to develop every drug all the way and no revenue from any products
I knew there was a chance we would do something like this, but thought it low. We are basically betting on FHCO's ability to select strong drug candidates and guide them through the FDA process. They believe this to be part of their expertise. However, I don't know how to evaluate what they just purchased.
When tenders are awarded, there is no guarantee the vendor gets any actual orders. Take South Africa, where FHCO was awarded 20% back in 2013 but ended up sullying more than 50% of the whole tender. I suspect the same will be true for the UNFPA awards, though suspect FHCO received the vast majority of it anyway. The biggest issue is training, which costs just as much as the condoms themselves. Govt staff and users already know how to use FHCO's product. This is not the case with competitors. These products all have different designs. with Cupid's possessing a sponge. FC2 looks more like a male condom, albeit one big enough for a rhinocerous.
Given Brazil is a year late, it's tough to disagree with you. Payment would be to Semina in Real which owes FhCO in $$$$, which is further risk if Semina is not hedged.
Yeah, well it went from $4.00 to $1.30 on basically no news as well. 2015 results were stellar throughout the year, though agree they need to get paid by Brazil. When they get paid, it's a $3 stock.